Nuevolution AB
https://nuevolution.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nuevolution AB
Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution
Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.
Company Information
- Other Names / Subsidiaries
-
- Nuevolution A/S
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice